Blog
RSS FeedPosted by Michael Wonder on 05 Dec 2018
NICE terminates two appraisals
5 December 2018 - NICE is unable to make a recommendation about the use of two medicines in the NHS because ...
Posted by Michael Wonder on 04 Dec 2018
Flexibility on cancer drugs approval will foster innovation
4 December 2018 - Between 2000 and 2016, no new drugs were approved for cancers of the brain, and there were ...
Posted by Michael Wonder on 04 Dec 2018
New cancer drugs taking longer to reach NHS patients
4 December 2018 - NHS patients are waiting longer for new cancer drugs because of delays in taking them through ...
Posted by Michael Wonder on 30 Nov 2018
NICE U turn on Opdivo for skin cancer recurrence
30 November 2018 - NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence ...
Posted by Michael Wonder on 29 Nov 2018
Life extending treatment for patients with advanced liver cancer recommended by NICE
29 November 2018 - Approving regorafenib is a "welcome step forward" for those people who are eligible. ...
Posted by Michael Wonder on 22 Nov 2018
New life-extending lung cancer treatment approved by NICE
22 November 2018 - NICE today recommends in draft guidance that immunotherapy drug pembrolizumab (also known as Keytruda), used with ...
Posted by Michael Wonder on 19 Nov 2018
Innovative skin cancer drug available on Cancer Drugs Fund
19 November 2018 - Patients with a type of advanced skin cancer have a new treatment option as pembrolizumab, also known ...
Posted by Michael Wonder on 16 Nov 2018
NICE recommends cutting-edge therapy for young people with blood cancer
16 November 2016 - NICE has recommended a pioneering cancer treatment, CART-cell therapy, for people under the age of 25 with ...
Posted by Michael Wonder on 10 Nov 2018
NICE says no to expanding use of AstraZeneca's’ Lynparza
9 November 2018 - NICE has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian ...
Posted by Michael Wonder on 09 Nov 2018
Lenvima backed for NHS use to treat liver cancer
9 November 2018 - NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and ...
Posted by Michael Wonder on 26 Oct 2018
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
26 October 2018 - NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not ...
Posted by Michael Wonder on 20 Oct 2018
Some European countries decide to cover cancer drugs much faster than others
19 October 2018 - Some European countries take more than twice as long as others to decide whether to provide ...
Posted by Michael Wonder on 19 Oct 2018
NICE rejects Lilly’s breast cancer drug Verzenios
19 October 2018 - As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast ...
Posted by Michael Wonder on 18 Oct 2018
NHS green light for Novartis skin cancer combo
18 October 2018 - The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available ...
Posted by Michael Wonder on 08 Oct 2018
NICE expands backing for Pfizer’s Mylotarg
8 October 2018 - NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with ...